Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity

ClinicalTrials.gov ID

NCT07135141

Lead Sponsor

Beijing Friendship HospitalOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

256Estimated

Last Update Posted

Aug 21, 2025Actual

Start Date

Sep 30, 2025Estimated

Primary Completion Date

Sep 30, 2027Estimated

Completion Date

Sep 30, 2029Estimated

Official Title

Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity:A Multicenter, Randomized, Double-Blind, Placebo-Controlled Superiority Trial

Brief Summary

The SMART study is a 96-week, multicenter, randomized, double-blind, placebo-controlled superiority clinical trial. A total of 256 severe obesity patients are randomized 1:1 to either receive the bariatric surgery plus GCG/GLP-1 dual receptor agonist group (receiving sleeve gastrectomy followed by subcutaneous injections of mazdutide weekly, with stepwise dose escalation to a maintenance dose per protocol) or the bariatric surgery plus placebo group (receiving matched procedure plus placebo injections). The primary objective is to evaluate the potential enhancing weight reduction effects of the combination therapy with bariatric surgery and mazdutide measured by the percentage change of excess weight loss.

• Severe Obesity

• Sleeve gastrectomy plus early mazdutide initiation
• Sleeve gastrectomy followed with early mazdutide placebo initation

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Aged 18-70 years (inclusive), male or female;
• BMI≥37.5 kg/m2, with or without obesity-related complications;
• Planned to take sleeve gastrectomy
• Understand the trial protocol, voluntarily sign the informed consent form (ICF), and agree to follow all study requirements and restrictions.

Exclusion Criteria:

• Previous gastrointestinal surgery such as stomach and duodenum, or weight loss and metabolic surgery;
• History of thyroid C-cell carcinoma, multiple endocrine neoplasia (MEN) 2A or 2B, or relevant family history;
• ALT > 3.0 × ULN (if NAFLD is diagnosed at screening and within 6 months prior to screening, ALT ≤ 5.0 × ULN can be enrolled), or AST > 3.0 ×ULN, or total bilirubin (TBIL) > 2 × ULN
• Estimated glomerular filtration rate eGFR < 45 mL/min/1.73 m2 using the CKD-EPI equation
• Chronic anemia：Hemoglobin < 110 g/L (males) or < 100 g/L (females)；
• Have the following 12-lead electrocardiogram (ECGs) abnormalities at screening(<50 beats/min or >100 beats/min), 2nd or 3rd degree atrioventricular block, long QT syndrome or QTcF > 450 ms (males), QTcF > 470 ms (females), left or right bundle branch block, pre-excitation syndrome, or other significant arrhythmia (except sinus arrhythmia);
• Acute hyperglycemic/hypoglycemic events within 1 year, including:

diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state (HHS), and hypoglycemic coma, etc;

• Participants with previous severe myocardial infarction, stroke, acute and chronic heart failure, cardiac procedure such as percutaneous coronary intervention, coronary artery bypass grafting, or are not suitable for participation in this study after the investigator's assessment;
• Previous or confirmed mental illness at screening/randomization phase[Previous moderate to severe depressionPHQ questionnaire (Depression Screening Scale) ≥ 15 points, C-SSRS questionnaire (Columbia Suicide Severity Scale) category 4 or 5 at screening or randomization, or "Yes" in suicidal behavior or suicidal ideation];
• Previous specific infectious diseases, incl. acquired immunodeficiency syndrome, viral hepatitis B, viral hepatitis C, etc;
• End-stage disease with an expected survival of less than 5 years or previous/current malignancy;
• Use of GLP-1 receptor (GLP-1R) agonists or GLP-1R/GCGR agonists or GIPR/GLP-1R agonists or GIPR/GLP-1R/GCGR agonists within three months prior to screening;
• History of alcohol or drug abuse at screening;
• History of specific drugs use beyond 2 times, incl. moderate anticholinergics, antiparkinsonians, antiepileptic drugs, antipsychotics, benzodiazepines and sedatives, morphine and narcotic analgesics, stimulant drugs, medical marijuana, marijuana, and cannabidiol, etc.;
• Pregnant or lactating females, males or females of childbearing potential who are not willing to use contraception throughout the study and for 8 weeks after the end of the study;
• Having participated in other clinical investigators who have a conflict of interest with this study;
• The investigator suspects that the participant may be allergic to ingredients in the study drug or drugs of the same class;

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Triple

Lead Sponsor

Beijing Friendship HospitalOTHER

jiln@bjmu.edu.cn+86 010 63139361

zly8128@csu.edu.cn+86 19373109453

+86 13881823928

liushaozhuang@sdu.edu.cn+86 18560085165

1551389142@qq.com+86 15877990129

sunxitai@hotmail.com+86 13815424927

yangu@fudan.edu.cn+86 13661756660

litao18353@163.com+86 13930483525

liangxiaoyu2025@hotmail.com+86 13802036941

kamei_li@163.com+86 15071396243

• Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity

  NCT07657676

  Not yet recruitingInterventionalPhase 4Updated Aug 28, 2026
• A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

  NCT06124807

  CompletedInterventionalPhase 2Updated Apr 21, 2026
• ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management

  NCT07517042

  RecruitingInterventionalNot ApplicableUpdated Apr 8, 2026
• Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss

  NCT06734273

  RecruitingInterventionalEarly Phase 1Updated May 8, 2026
• Endoscopic Gastric Mucosal Devitalization (GMD) as a Primary Obesity Therapy - Part 2

  NCT03638843

  CompletedInterventionalNot ApplicableUpdated Jul 20, 2021
• Endoscopic Gastric Mucosal Devitalization (GMD) as a Primary Obesity Therapy

  NCT03526263

  CompletedInterventionalNot ApplicableUpdated Sep 24, 2019